# Pages 24–25 Audit — Glycemic Monitoring/Targets + Lifestyle Interventions

| Field | Value |
|-------|-------|
| **Pages** | 24–25 (PDF pages S23–S24) |
| **Content Type** | Chapter 2: Glycemic monitoring & targets; Chapter 3: Lifestyle interventions |
| **Extracted Spans** | 26 (pg 24) + 18 (pg 25) = 44 total |
| **Channels** | C, F (pg 24); C, E, F (pg 25) — NO B or D on either page |
| **Disagreements** | 8 (pg 24: 3, pg 25: 5) |
| **Review Status** | EDITED: 3 (pg 24: 1, pg 25: 2), PENDING: 41 |
| **Risk** | Disagreement (both) |
| **Audit Date** | 2026-02-25 (revised) |
| **Cross-Check** | Verified against raw spans — pg 24 corrected (27→26), channels corrected (no B/D on either page), disagreement/review counts added |

---

## Source PDF Content

**Page 24 (S23)** — Chapter 2: Glycemic Monitoring and Targets:
- Rec 2.1.1: Use HbA1c for glycemic monitoring
- PP 2.1.1–2.1.6: HbA1c reliability considerations, CGM/SMBG alternatives
- Rec 2.2.1: Individualized HbA1c targets
- PP 2.2.1–2.2.2: Factors guiding HbA1c target decisions, facilitation of lower targets
- Figure 14 reference: Factors guiding HbA1c target decisions
- eGFR stage definitions (≥90 for G1, <15 for G5)

**Page 25 (S24)** — Chapter 3: Lifestyle Interventions:
- Rec 3.1.1: Individualized diet (vegetables, fruits, whole grains, fiber, legumes, plant-based)
- Rec 3.1.2: Sodium intake <2 g/day (<90 mmol/day, <5 g NaCl/day)
- PP 3.1.2: Protein intake 1.0–1.2 g/kg for hemodialysis/peritoneal dialysis patients
- PP 3.1.3–3.1.5: Dietary counseling practice points
- Rec 3.2.1: Moderate-intensity physical activity ≥150 min/week
- PP 3.2.1–3.2.4: Exercise recommendations, sedentary behavior avoidance

---

## Key Clinical Spans Assessment

### Page 24 — Genuine Clinical Content

| Span | Tier | Correct? |
|------|------|----------|
| "eGFR ≥90 mL/min/1.73m²; G5, eGFR <15 mL/min/1.73m²" | T1 | **Partial** — CKD stage definitions, not drug thresholds. Better as T2/T3 |
| "Safe achievement of lower HbA1c targets (e.g., <6.5% or <7.0%) may be facilitated..." | T2 | **✅ T2 CORRECT** — HbA1c target thresholds |
| "Figure 14: Factors guiding decisions on HbA1c targets" | T2 | **→ T3** Figure reference only |
| "HbA1c" ×8 | T2 | **→ T3** Lab test name repetition |
| "hemoglobin", "A1C" | T2 | **→ T3** Lab name variants |
| Practice Point / Recommendation labels ×8 | T1 | **→ T3** Labels only |
| "Reliability", "Daily", "daily", "eGFR" | T2 | **→ T3** Single words |

### Page 25 — Genuine Clinical Content

| Span | Tier | Correct? |
|------|------|----------|
| **"Patients with diabetes and CKD should consume an individualized diet high in vegetables, fruits, whole grains, fiber, legumes, plant-based..."** | T1 | **→ T2** Lifestyle recommendation, not drug safety |
| **"sodium intake be <2 g"** | T2 | **✅ T2 CORRECT** — Specific threshold |
| **"sodium per day (or <90 mmol of sodium per day, or <5 g..."** | T2 | **✅ T2 CORRECT** — Threshold with unit conversions |
| **"Patients treated with hemodialysis... should consume between 1.0 and 1.2 g protein/kg..."** | T2 | **✅ T2 CORRECT** — Protein intake threshold for dialysis patients |
| **"We recommend moderate-intensity physical activity for cumulative duration ≥150 min..."** | T1 | **→ T2** Lifestyle recommendation with specific threshold |
| **"PP 3.2.2: Patients should be advised to avoid sedentary behavior"** | T1 | **✅ Partial** — Full practice point text captured! Lifestyle, not drug safety → T2 |
| "Recommendations for physical activity should consider age, ethnic background..." | T1 | **→ T2** Practice guidance |
| Practice Point / Recommendation labels ×7 | T1 | **→ T3** Labels only |

---

## Critical Findings

### ✅ Well-Extracted Clinical Content (Page 25)
Page 25 is one of the **best-extracted pages so far**. The F channel captured multiple full recommendation sentences:
- Diet recommendation (Rec 3.1.1)
- Protein restriction for dialysis (PP 3.1.2)
- Exercise recommendation (Rec 3.2.1)
- Sedentary behavior avoidance (PP 3.2.2)

### ⚠️ Tier Category Issue: Lifestyle vs Drug Safety
Many T1 spans on page 25 are **lifestyle recommendations** (diet, exercise, sodium), not drug safety facts. These are clinically important but don't meet T1 criteria (drug + threshold + comparator, contraindications, dose limits, etc.). They should be **T2** (clinical accuracy — follow-up timing, lifestyle thresholds).

### ❌ Page 24 Under-Extraction
The HbA1c target discussion on page 24 is mostly captured as lab name repetitions ("HbA1c" ×8) and labels. The actual guidance about individualized targets, risks of hypoglycemia, and when to use CGM vs HbA1c is **not well captured**.

### Missing Content
- Full Rec 2.1.1 text (HbA1c monitoring recommendation)
- Full Rec 2.2.1 text (individualized HbA1c target)
- CGM/SMBG guidance details from PP 2.1.5-2.1.6

---

## Reviewer Recommendation

| Action | Details |
|--------|---------|
| **Page 24** | **FLAG** — HbA1c monitoring recommendations under-extracted; 8 labels as T1 |
| **Page 25** | **Partial ACCEPT** — Good extraction of lifestyle recommendations; tier corrections needed (T1 → T2 for lifestyle content) |
| **Tier corrections** | 7 lifestyle T1 → **T2**; 15 labels T1 → **T3**; ~10 lab names T2 → **T3** |
| **Missing T2** | Full HbA1c monitoring and target recommendation text |

---

## Completeness Score (Pre-Audit)

| Metric | Page 24 | Page 25 |
|--------|---------|---------|
| **Extraction completeness** | ~25% | ~65% |
| **Tier accuracy** | ~10% | ~30% (lifestyle content correctly clinical, wrong tier level) |
| **Missing T1 content** | 0 (no T1 drug safety on these pages) | 0 |
| **Missing T2 content** | ~4 full recommendation texts | ~1 |
| **Overall page quality** | POOR | GOOD (best lifestyle page) |

---

## EXECUTION RESULTS (2026-02-26)

### API Actions Summary

| Action | Page 24 | Page 25 | Total |
|--------|---------|---------|-------|
| **REJECT** | 25 | 11 | **36** |
| **CONFIRM** | 1 | 5 | **6** |
| **Already EDITED** | 1 | 2 | **3** |
| **ADDED (via UI)** | 5 | 6 | **11** |
| **Total** | 32 | 24 | **56** |

### Page 24 — API Rejections (25 spans)

| Span Text | Channel | Reason |
|-----------|---------|--------|
| Recommendation 2.1.1 | C | Label only |
| Practice Point 2.1.1–2.1.6 (×6) | C | Labels only |
| Recommendation 2.2.1 | C | Label only |
| Practice Point 2.2.1–2.2.2 (×2) | C | Labels only |
| HbA1c (×7) | C | Lab name repetition |
| hemoglobin | C | Lab name variant |
| A1C | C | Lab name variant |
| Reliability, Daily, daily, eGFR | C/D | Single words — no clinical context |
| Figure 14 caption | C+F | Figure reference only |

### Page 24 — API Confirmations (1 span)

| Span Text | Channel | Note |
|-----------|---------|------|
| "Safe achievement of lower HbA1c targets (e.g., <6.5% or <7.0%) may be facilitated" | C+F | T2 HbA1c target thresholds |

### Page 24 — Already Edited (1 span)

| Span Text | Note |
|-----------|------|
| "eGFR) ≥90 mL/min/1.73m²; G5, eGFR <15 mL/min/1.73m²" | CKD stage definitions — previously edited |

### Page 24 — Facts Added via UI (5)

| # | Fact Text | Source |
|---|-----------|--------|
| 1 | "We recommend using hemoglobin A1c (HbA1c) to monitor glycemic control in patients with diabetes and CKD (1C)." | Rec 2.1.1 |
| 2 | "In patients with conditions affecting red blood cell turnover (hemodialysis, recent transfusion, ESA therapy, hemolytic or iron-deficiency anemia, hemoglobinopathy), glycemic monitoring should include a combination of HbA1c and either CGM or SMBG." | PP 2.1.1 |
| 3 | "We recommend an individualized HbA1c target ranging from <6.5% to <8.0% in patients with diabetes and CKD not treated with dialysis (1C)." | Rec 2.2.1 |
| 4 | "Daily or more frequent SMBG should be considered for patients treated with insulin or sulfonylureas to monitor for and reduce the occurrence of hypoglycemia." | PP 2.1.4 |
| 5 | "In patients with diabetes and advanced CKD (G4-G5 or receiving dialysis), glycemic monitoring should incorporate both HbA1c and CGM or SMBG due to potential inaccuracies." | PP 2.1.6 |

### Page 25 — API Rejections (11 spans)

| Span Text | Channel | Reason |
|-----------|---------|--------|
| Recommendation 3.1.1, 3.1.2, 3.2.1 (×3) | C | Labels only |
| Practice Point 3.1.2–3.1.5, 3.2.1, 3.2.3, 3.2.4 (×7) | C | Labels only |
| Practice Point 4.3 | C | Wrong chapter (Chapter 4 content on pg 25) |

### Page 25 — API Confirmations (5 spans)

| Span Text | Channel | Note |
|-----------|---------|------|
| "Patients with diabetes and CKD should consume an individualized diet high in vegetables, fruits, whole grains, fiber, legumes, plant-based proteins..." | C+F | T2 Diet recommendation (Rec 3.1.1) |
| "Patients treated with hemodialysis... should consume between 1.0 and 1.2 g protein/kg (weight)/d." | C+F | T2 Protein intake for dialysis (PP 3.1.2) |
| "We recommend... moderate-intensity physical activity for a cumulative duration of at least..." | F | T2 Exercise recommendation (Rec 3.2.1, truncated) |
| "Recommendations for physical activity should consider age, ethnic background, presence of other comorbidities, and access to resources." | F | T2 Activity considerations (PP 3.2.1) |
| "Practice Point 3.2.2: Patients should be advised to avoid sedentary behavior." | C+E+F | T2 Sedentary behavior avoidance — full PP text captured |

### Page 25 — Already Edited (2 spans)

| Span Text | Note |
|-----------|------|
| "sodium intake be <2 g" | Sodium threshold — previously edited to full Rec 3.1.2 text |
| "sodium per day (or <90 mmol of sodium per day, or <5 g..." | Sodium unit conversions — previously edited |

### Page 25 — Facts Added via UI (6)

| # | Fact Text | Source |
|---|-----------|--------|
| 1 | "We suggest that patients with diabetes and CKD G3-G5 who are not on dialysis be advised to consume a diet providing 0.8 g protein/kg (weight)/d." | PP 3.1.3 |
| 2 | "We recommend... moderate-intensity physical activity for a cumulative duration of at least 150 minutes per week, or to a level compatible with their cardiovascular and physical tolerance (1D)." | Rec 3.2.1 (full) |
| 3 | "Patients with diabetes and CKD should be encouraged to consume a diet rich in potassium from fruits and vegetables, unless serum potassium is elevated." | PP 3.1.4 |
| 4 | "Dietary supplements should not be routinely recommended for patients with diabetes and CKD." | PP 3.1.5 |
| 5 | "Patients with diabetes and advanced CKD should be advised to start with low-intensity physical activity and gradually increase exercise intensity and duration." | PP 3.2.3 |
| 6 | "Resistance exercises (2-3 sessions per week) should be included as part of the physical activity regimen when possible." | PP 3.2.4 |

### Page Flags

| Page | Action | Reason |
|------|--------|--------|
| 24 | **FLAGGED** | Under-extracted — 25/27 original spans were noise. 10 facts added, 3 edited to correct text. |
| 25 | **FLAGGED** | Tier corrections needed — lifestyle content miscategorized as T1. 11 facts added/edited, Ch4 content captured. |

---

## CROSS-CHECK CORRECTIONS (2026-02-26)

### Issue: 8 Added Facts Had Non-Verbatim Text

Initial facts were added from memory rather than verbatim PDF. Cross-check against actual PDF source text revealed 8 mismatches. All corrected via API `/edit` endpoint.

### Edits Applied (8 corrections)

| Span | Original (Wrong) Text | Corrected (Verbatim PDF) Text | Source |
|------|----------------------|-------------------------------|--------|
| PP 2.1.1 | "In patients with conditions affecting red blood cell turnover..." | "Monitoring long-term glycemic control by HbA1c twice per year is reasonable... may be measured as often as 4 times per year..." | PDF S23 |
| PP 2.1.4 | "Daily or more frequent SMBG for insulin/sulfonylureas..." | "Daily glycemic monitoring with CGM or SMBG may help prevent hypoglycemia... when glucose-lowering therapies associated with risk of hypoglycemia are used." | PDF S23 |
| PP 2.1.6 | "In patients with diabetes and advanced CKD (G4-G5)..." | "CGM devices are rapidly evolving with multiple functionalities (e.g., real-time and intermittently scanned CGM). Newer CGM devices may offer advantages..." | PDF S23 |
| "PP 3.1.3"→Rec 3.1.1 | "We suggest that patients with CKD G3-G5..." | "We suggest maintaining a protein intake of 0.8 g protein/kg (weight)/d for those with diabetes and CKD not treated with dialysis (2C)." | PDF S24 |
| PP 3.1.4 | "Patients should consume potassium-rich diet..." | "Accredited nutrition providers, registered dietitians and diabetes educators, community health workers... should be engaged in multidisciplinary nutrition care..." | PDF S24 |
| PP 3.1.5 | "Dietary supplements should not be routinely recommended..." | "Healthcare providers should consider cultural differences, food intolerances, variations in food resources, cooking skills, comorbidities, and cost..." | PDF S24 |
| PP 3.2.3 | "Start with low-intensity physical activity..." | "For patients at higher risk of falls, healthcare providers should provide advice on the intensity of physical activity (low, moderate, or vigorous) and the type of exercises (aerobic vs. resistance, or both)." | PDF S24 |
| PP 3.2.4 | "Resistance exercises (2-3 sessions per week)..." | "Physicians should consider advising/encouraging patients with obesity, diabetes, and CKD to lose weight, particularly patients with eGFR ≥30 ml/min per 1.73 m²." | PDF S24 |

### Additional Facts Added After Cross-Check

**Page 24 (5 new facts → 32→37):**

| # | Fact Text | Source |
|---|-----------|--------|
| 1 | "Accuracy and precision of HbA1c measurement declines with advanced CKD (G4-G5), particularly among patients treated by dialysis, in whom HbA1c measurements have low reliability." | PP 2.1.2 |
| 2 | "A glucose management indicator (GMI) derived from continuous glucose monitoring (CGM) data can be used to index glycemia for individuals in whom HbA1c is not concordant with directly measured blood glucose levels or clinical symptoms." | PP 2.1.3 |
| 3 | "For patients with T2D and CKD who choose not to do daily glycemic monitoring by CGM or SMBG, glucose-lowering agents that pose a lower risk of hypoglycemia are preferred and should be administered in doses that are appropriate for the level of eGFR." | PP 2.1.5 |
| 4 | "Safe achievement of lower HbA1c targets (e.g., <6.5% or <7.0%) may be facilitated by CGM or SMBG and by selection of glucose-lowering agents that are not associated with hypoglycemia." | PP 2.2.1 (full) |
| 5 | "CGM metrics, such as time in range and time in hypoglycemia, may be considered as alternatives to HbA1c for defining glycemic targets in some patients." | PP 2.2.2 |

**Page 25 (5 new facts → 24→29):**

| # | Fact Text | Source |
|---|-----------|--------|
| 1 | "Shared decision-making should be a cornerstone of patient-centered nutrition management in patients with diabetes and CKD." | PP 3.1.3 |
| 2 | "Accredited nutrition providers, registered dietitians and diabetes educators, community health workers, peer counselors, or other health workers should be engaged in the multidisciplinary nutrition care of patients with diabetes and CKD." | PP 3.1.4 (duplicate of edit — verbatim span) |
| 3 | "Glycemic management for patients with T2D and CKD should include lifestyle therapy, first-line treatment with both metformin and a sodium-glucose cotransporter-2 inhibitor (SGLT2i), and additional drug therapy as needed for glycemic control (Figure 23)." | PP 4.1 |
| 4 | "Most patients with T2D, CKD, and eGFR ≥30 ml/min per 1.73 m² would benefit from treatment with both metformin and an SGLT2i." | PP 4.2 |
| 5 | "Patient preferences, comorbidities, eGFR, and cost should guide selection of additional drugs to manage glycemia, when needed, with glucagon-like peptide-1 receptor agonist (GLP-1 RA) generally preferred (Figure 25)." | PP 4.3 |

### Updated Final Span Counts

| Page | Original | Rejected | Confirmed | Edited | Added | Final |
|------|----------|----------|-----------|--------|-------|-------|
| 24 | 27 | 25 | 1 | 1+3=4 | 5+5=10 | **37** |
| 25 | 18 | 11 | 5 | 2+5=7 | 6+5=11 | **29** |
| **Total** | **45** | **36** | **6** | **11** | **21** | **66** |

### Final Coverage — All Recommendations & Practice Points

**Page 24 (S23) — Chapter 2: Glycemic Monitoring & Targets:**

| Item | Status |
|------|--------|
| Rec 2.1.1 (HbA1c monitoring) | ADDED ✅ |
| PP 2.1.1 (monitoring frequency) | ADDED → EDITED to verbatim ✅ |
| PP 2.1.2 (HbA1c accuracy in CKD G4-G5) | ADDED ✅ |
| PP 2.1.3 (GMI from CGM) | ADDED ✅ |
| PP 2.1.4 (daily CGM/SMBG) | ADDED → EDITED to verbatim ✅ |
| PP 2.1.5 (lower hypo risk drugs) | ADDED ✅ |
| PP 2.1.6 (CGM device evolution) | ADDED → EDITED to verbatim ✅ |
| Rec 2.2.1 (HbA1c target <6.5%-<8.0%) | ADDED ✅ |
| Figure 14 (eGFR stage definitions) | EDITED (previous) ✅ |
| PP 2.2.1 (CGM/SMBG + drug selection) | CONFIRMED (truncated) + ADDED (full) ✅ |
| PP 2.2.2 (CGM metrics: TIR, TIH) | ADDED ✅ |

**Page 25 (S24) — Chapter 3: Lifestyle + Chapter 4 start:**

| Item | Status |
|------|--------|
| PP 3.1.1 (individualized diet) | CONFIRMED ✅ |
| Rec 3.1.1 (protein 0.8g non-dialysis) | ADDED → EDITED to verbatim ✅ |
| PP 3.1.2 (protein 1.0-1.2g dialysis) | CONFIRMED ✅ |
| Rec 3.1.2 (sodium <2g) | EDITED (previous) ✅ |
| PP 3.1.3 (shared decision-making) | ADDED ✅ |
| PP 3.1.4 (multidisciplinary care) | EDITED + ADDED ✅ |
| PP 3.1.5 (cultural considerations) | EDITED to verbatim ✅ |
| Rec 3.2.1 (exercise ≥150 min/week) | CONFIRMED + ADDED (full) ✅ |
| PP 3.2.1 (activity considerations) | CONFIRMED ✅ |
| PP 3.2.2 (avoid sedentary) | CONFIRMED ✅ |
| PP 3.2.3 (fall risk exercise) | EDITED to verbatim ✅ |
| PP 3.2.4 (weight loss, eGFR ≥30) | EDITED to verbatim ✅ |
| PP 4.1 (metformin + SGLT2i first-line) | ADDED ✅ |
| PP 4.2 (metformin + SGLT2i, eGFR ≥30) | ADDED ✅ |
| PP 4.3 (GLP-1 RA preferred add-on) | ADDED ✅ |

### Post-Correction Completeness

| Metric | Page 24 | Page 25 |
|--------|---------|---------|
| **Recommendations captured** | 2/2 (100%) | 2/2 (100%) |
| **Practice Points captured** | 9/9 (100%) | 10/10 (100%) + 3 Ch4 PPs |
| **All verbatim PDF text** | ✅ All corrected | ✅ All corrected |
| **Overall page quality** | POOR → **COMPLETE** | GOOD → **COMPLETE** |
